Achondroplasia is the most common of the skeletal dysplasias that result in marked short
stature (dwarfism). Although its clinical and radiologic phenotype has been described for …

Autosomal dominant mutations in fibroblast growth factor receptor 3 (FGFR3) cause
achondroplasia (Ach), the most common form of dwarfism in humans, and related …

Background There are no effective therapies for achondroplasia. An open-label study
suggested that vosoritide administration might increase growth velocity in children with …

The effectiveness of many anticancer drugs depends on the creation of specific metabolites
that may alter their therapeutic or toxic properties. One significant route of biotransformation …

The fibroblast growth factor (FGF) family is composed of 18 secreted signaling proteins
consisting of canonical FGFs and endocrine FGFs that activate four receptor tyrosine …

Infigratinib (TRUSELTIQ TM), a fibroblast growth factor receptor (FGFR)-specific tyrosine
kinase inhibitor, is being co-developed by QED Therapeutics and Helsinn for the treatment …

Fibroblast growth factor (FGF) signaling through its receptors, FGFR1, FGFR2, FGFR3, or
FGFR4, regulates cell fate, angiogenesis, immunity, and metabolism. Dysregulated FGF …

Achondroplasia is a genetic disorder that results in disproportionate short stature. The true
prevalence of achondroplasia is unknown as estimates vary widely. This systematic …

Chondrodystrophy in dogs is defined by dysplastic, shortened long bones and premature
degeneration and calcification of intervertebral discs. Independent genome-wide …

Achondroplasia, the most common form of disproportionate short stature, is caused by a
variant in the fibroblast growth factor receptor 3 (FGFR3) gene. Advances in drug treatment …